Effect of combined treatment with insulin, metformin, and gliclazide on the expression and activity of Akt, mTOR, and p70S6K protein kinases in lymphocytes of diabetic patients

Authors

  • L.K. Sokolova V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kiev
  • V.M. Pushkarev V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kiev
  • Yu.B. Belchina V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kiev
  • V.V. Pushkarev V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kiev
  • T.S. Vatseba V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kiev
  • M.D. Tronko V.P. Komisarenko Institute of Endocrinology and Metabolism of the NAMS of Ukraine, Kiev

DOI:

https://doi.org/10.15407/dopovidi2018.08.105

Keywords:

Akt, diabetes mellitus, gliclazide, insulin, metformin, mTOR, p70S6K

Abstract

The expression of the main effector protein kinase Akt of the PI3K signaling pathway and the activities of mTOR and p70S6K protein kinases in lymphocytes of patients with diabetes mellitus are determined at the combination treatment with insulin and hypoglycemic drugs. It is shown that the Akt expression is reduced in blood mononuclear cells of patients with diabetes of the 2nd and, to a less extent, type 1. The activities of mTOR and p70S6K are also reduced in lymphocytes of patients with type 2 diabetes. Possible mechanisms of inhibiting the expression and activity of protein kinases are discussed.

Downloads

References

Tronko, M. D., Kovzun, O. I. & Pushkarev, V. M. (2012). Reception and the intracellular mechanisms of in- sulin effect. J. NAMS Ukraine, 4, pp. 430-437 (in Russian).

Verg è s, B. & Cariou, B. (2015). mTOR inhibitors and diab etes. Diabetes Res. Clin. Pract., 110, No. 2, pp. 1 01-108.

Standards of medical care in diabetes — 2018. (2018). Diabetes Care., 41, No. 1, pp. S1-S2. doi: https://doi.org/10.2337/dc18-Sint01

Pushkarev, V. V., Kovzun, O.I., Pushkarev, V. M. & Tronko, M. D. The effect of the combined action of ros- covitine and paclitaxel on the apoptotic and cell c ycle regulatory mechanisms in colon and anaplastic thy- roid cancer cells. ISRN Biochemistry, 2012, No. 826305, pp. 1-6. doi: https://doi.org/10.5402/2012/826305

Sokolova, L. K., Pushkarev, V. M., Belchina, Yu. B., Pushkarev, V. V. & Tronko, M. D. (2017). The activity of adenosine monophosphate-activated protein kinase in lymphocytes under the action of hypoglycemic drugs . Dopov. Nac. akad. nauk Ukr., No. 6, pp. 96-100 (in Russian). doi: https://doi.org/10.15407/dopovidi2017.06.096

Jeong, K. J., Kim, G. W. & Chung, S. H. (2014). AMP-activated protein kinase: An emerging target for gin- seng. J. Ginseng Res., 38, pp. 83-88. doi: https://doi.org/10.1016/j.jgr.2013.11.014

Dann, S. G., Selvaraj, A. & Thomas, G. (2007). mTOR Complex1-S6K1 signaling: at the crossroads of obe sity, diabetes and cancer. Trends Mol. Med., 13, No. 6, pp. 252-259. doi: https://doi.org/10.1016/j.molmed.2007.04.002

Saxton, R. A. & Sabatini, D. M. (2017). mTOR signaling in growth, metabolism, and disease. Cell., 168, No. 6, pp. 960-976. doi: https://doi.org/10.1016/j.cell.2017.02.004

Yuan, T., Rafizadeh, S., Gorrepati, K. D., Lupse, B., Oberholzer, J., Maedler, K. & Ardestani, A. (2017). Reciprocal regulation of mTOR complexes in pancreatic islets from humans with type 2 diabetes. Diabeto lo- gia, 60, No. 4, pp. 668-678. doi: https://doi.org/10.1007/s00125-016-4188-9

Ben-Sahra, I., Hoxhaj, G., Ricoult, S. J., Asara, J. M. & Manning, B. D. (2016). mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science, 351, pp. 728-733. doi: https://doi.org/10.1126/science.aad0489

Jones, R. G. & Pearce, E. J. (2017). MenTORing immunity: mTOR signaling in the development and func- tion of tissue-resident immune cells. Immunity. 46, No. 5, pp. 730-742. doi: https://doi.org/10.1016/j.immuni.2017.04.028

Lee, D. F., Kuo, H. P., Chen, C. T., Wei, Y., Chou, C. K., Hung, J. Y., Yen, C. J. & Hung, M. C. (2008). IKKbeta suppression of TSC1 function links the mTOR pathway with insulin resistance. Int. J. Mol. Med., 22, No. 5, pp. 633-638.

Khan, N. M., Ahmad, I. & Haqqi, T. M. (2018). Nrf2/ARE pathway attenuates oxidative and apoptotic re- sponse in human osteoarthritis chondrocytes by acti vating ERK1/2/ELK1-P70S6K-P90RSK signaling axis. Free Radic. Biol. Med., 116, pp. 159-171. doi: https://doi.org/10.1016/j.freeradbiomed.2018.01.013

Pushkarev, V. M., Sokolova, L. K., Pushkarev, V. V., Belchina, Yu. B. & Tronko, M. D. (2016). AMRK activity in lymphocytes of patients with diabetes mellitus under the influence of hypoglycemic drugs. Effect of met- formin. Probl. Endocrinol. Pathol., No. 4, pp. 29-35 (in Russian)

Downloads

Published

20.05.2024

How to Cite

Sokolova, L., Pushkarev, V., Belchina, Y., Pushkarev, V., Vatseba, T., & Tronko, M. (2024). Effect of combined treatment with insulin, metformin, and gliclazide on the expression and activity of Akt, mTOR, and p70S6K protein kinases in lymphocytes of diabetic patients . Reports of the National Academy of Sciences of Ukraine, (8), 105–109. https://doi.org/10.15407/dopovidi2018.08.105

Issue

No. 8 (2018): Reports of the National Academy of Sciences of Ukraine

Section

Medicine

License

Copyright (c) 2024 Reports of the National Academy of Sciences of Ukraine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Most read articles by the same author(s)

1 2 > >>